How have ABSCF shares performed in 2024?

AB Science's stock was trading at $2.55 at the start of the year. Since then, ABSCF shares have increased by 5.9% and is now trading at $2.70. View the best growth stocks for 2024 here .

Are investors shorting AB Science?

AB Science saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 8,000 shares, a decline of 87.3% from the March 15th total of 62,900 shares. Based on an average daily volume of 18,000 shares, the days-to-cover ratio is presently 0.4 days. View AB Science's Short Interest .

How do I buy shares of AB Science?

Shares of ABSCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:ABSCF

AB Science (ABSCF) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Buy ABSCF with Qtrade

Free ABSCF Stock Alerts

$2.70

0.00 (0.00%)

(As of 04/17/2024 ET)

Compare

Today's Range: $2.70
▼
$2.70
50-Day Range: $2.55
▼
$4.46
52-Week Range: $2.55
▼
$3.84

Volume: N/A
Average Volume: 39,925 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Headlines Short Interest

Get AB Science alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About AB Science Stock (OTCMKTS:ABSCF)

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company is also developing AB8939, a synthetic microtubule destabiliser for haematology indications. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.

ABSCF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ABSCF Stock News Headlines

April 18, 2024 | markets.businessinsider.com

AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure

April 12, 2024 | americanbankingnews.com

AB Science S.A. (OTCMKTS:ABSCF) Short Interest Down 87.3% in March

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 4, 2024 | msn.com

Brandon student off to science fair finals

April 3, 2024 | finance.yahoo.com

AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS

March 13, 2024 | finance.yahoo.com

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

March 7, 2024 | finance.yahoo.com

AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development

March 6, 2024 | finance.yahoo.com

AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

February 29, 2024 | finance.yahoo.com

AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET

February 26, 2024 | finance.yahoo.com

AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS

February 23, 2024 | msn.com

Science Center ranks among Top 5 USA Today's Readers' Choice Awards for 3 consecutive years

January 26, 2024 | finance.yahoo.com

AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency

January 15, 2024 | finance.yahoo.com

AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis

November 28, 2023 | finance.yahoo.com

AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease

November 27, 2023 | finance.yahoo.com

AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”

November 13, 2023 | morningstar.com

AB Science AB

October 31, 2023 | businessinsider.com

The head of AB InBev's entertainment studio has exited in the latest marketing shakeup at the Anheuser-Busch parent

September 29, 2023 | finance.yahoo.com

AB Science today reports its revenues for the first half of 2023 and provides an update on its activities

September 25, 2023 | yahoo.com

ABC Moves Forward With ‘Dancing With the Stars’ Premiere After Considering Delay

September 25, 2023 | abcnews.go.com

Interest rates will stay high 'as long as necessary': European Central Bank leader

September 22, 2023 | abcnews.go.com

The U.N. system is 'sclerotic and hobbled' and needs urgent reform, top European Union official says

September 18, 2023 | finance.yahoo.com

AB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALS

September 14, 2023 | abcnews.go.com

European Central Bank raises interest rates for the 10th time in a row to fight inflation despite weak economic growth

September 11, 2023 | abcnews.go.com

Western Balkan heads of state press for swift approval of their European Union membership bids

September 11, 2023 | abcnews.go.com

European Union home affairs chief appeals for release of Swedish EU employee held in Iranian prison

September 11, 2023 | msn.com

Australia politics live: Labor dismisses Greens’ attempt to debate Chilean coup as ‘grandstanding’

See More Headlines

Receive ABSCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AB Science and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: OTCMKTS:ABSCF
CUSIP: N/A
CIK: N/A
Web: www.ab-science.com
Phone: (314) 720-0014
Fax: N/A
Employees: 89
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Alain Moussy MBA
Co-Founder, Chairman, President, CEO, MD & Scientific Director
Mr. Laurent Guy MBA
Chief Financial Officer
Mr. Christian FASSOTTE
Global Chief Medical Officer
Mr. Alexis BERNARD
Head of Veterinary Sales
Mr. Harshad KULKARNI
Head of Statistics
Dr. Albert Ahn D.V.M.
President of USA Operations

Key Competitors

View All Competitors

ABSCF Stock Analysis - Frequently Asked Questions

How have ABSCF shares performed in 2024?: AB Science's stock was trading at $2.55 at the start of the year. Since then, ABSCF shares have increased by 5.9% and is now trading at $2.70.
View the best growth stocks for 2024 here.
Are investors shorting AB Science?: AB Science saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 8,000 shares, a decline of 87.3% from the March 15th total of 62,900 shares. Based on an average daily volume of 18,000 shares, the days-to-cover ratio is presently 0.4 days.
View AB Science's Short Interest.
How do I buy shares of AB Science?: Shares of ABSCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ABSCF) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial